The Utah-based biotech company specializes in developing Q-Cells, a type of adult neural progenitor cell therapy that replaces the insulating myelin on damaged neurons and provides trophic support for restoring and preserving normal functions. Q-Cells are intended for the treatment of various diseases, including amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, cerebral palsy, and peripheral neuropathies. Q Therapeutics aims to provide specialized stem cells for use in neurodegenerative diseases, with a focus on ALS as the initial indication.